Sydney - Wednesday - September 6: (RWE Aust Business News) - Life
Therapeutics (ASX:LFE) will supply Cangene Corp with anti-anthrax plasma
to produce a hyperimmune product for the US Department of Health and
Human Services.
This is a $US143m project for Cangene under Project BioShield to
produce 10,000 doses of anthrax immune globulin for treating inhalational
anthrax.
LFE
life therapeutics limited
life therapeutics to supply anti anthrax plasma
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LFE (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online